Lamivudine treatment for acute hepatitis B after liver transplantation

Pietro Andreone, Paolo Caraceni, Gian Luca Grazi, Luca Belli, Gian Luigi Milandri, Giorgio Ercolani, Elio Jovine, Antonia D'Errico, Pier Roberto Dal Monte, Gaetano Ideo, Domenico Forti, Alighieri Mazziotti, Antonino Cavallari, Mauro Bernardi

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background/Aims: Acute hepatitis caused by recurrent or de novo hepatitis B virus (HBV) infection after liver transplantation frequently induces aggressive disease leading to liver failure. The aim of this study was to determine the efficacy and safety of lamivudine treatment in post- transplant acute hepatitis B. Method: Twelve patients with acute hepatitis B were started on lamivudine 100 mg po daily within 8 weeks of the appearance of HBsAg. One patient was excluded after I month because of hepatocellular carcinoma recurrence. Patients were followed for an average of 68.6 weeks (range 32-108), and were clinically and biochemically evaluated on a monthly basis. They had a histological assessment at baseline, after at least 6 months, and whenever clinically indicated. Results: Basal HBV-DNA ranged between 13 and 1288 pg/ml and serum alanine aminotransferase between 97 and 1036 U/l. HBV-DNA became undetectable within 8 weeks and transaminases normalized within 24 weeks in all cases. At the last visit, eight patients (73%) remained HBV-DNA negative by liquid hybridization and had normal or close to normal alanine aminotransferase. Five patients (45%) were also HBsAg negative and HBV-DNA negative by polymerase chain reaction. HBV-DNA and transaminase breakthrough occurred in three patients (27%). Histology after 6-9 months showed chronic hepatitis in seven patients. Lamivudine was well tolerated without serious adverse reactions. Conclusions: These results indicate that lamivudine treatment induces sustained inhibition of viral replication and normalization of transaminases in the majority of post- transplant patients with acute hepatitis B. HBsAg loss may be achieved in a considerable number of cases. Although viral resistance is relatively frequent, early initiation of lamivudine appears to be effective and safe.

Original languageEnglish
Pages (from-to)985-989
Number of pages5
JournalJournal of Hepatology
Volume29
Issue number6
DOIs
Publication statusPublished - Dec 1998

Fingerprint

Lamivudine
Hepatitis B
Liver Transplantation
Hepatitis B virus
Hepatitis B Surface Antigens
Transaminases
DNA
Therapeutics
Alanine Transaminase
Transplants
Liver Failure
Virus Diseases
DNA-Directed DNA Polymerase
Chronic Hepatitis
Hepatitis
Hepatocellular Carcinoma
Histology
Safety
Recurrence
Polymerase Chain Reaction

Keywords

  • Lamivudine
  • Liver transplantation
  • Recurrent or de novo acute hepatitis B

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Andreone, P., Caraceni, P., Grazi, G. L., Belli, L., Milandri, G. L., Ercolani, G., ... Bernardi, M. (1998). Lamivudine treatment for acute hepatitis B after liver transplantation. Journal of Hepatology, 29(6), 985-989. https://doi.org/10.1016/S0168-8278(98)80127-X

Lamivudine treatment for acute hepatitis B after liver transplantation. / Andreone, Pietro; Caraceni, Paolo; Grazi, Gian Luca; Belli, Luca; Milandri, Gian Luigi; Ercolani, Giorgio; Jovine, Elio; D'Errico, Antonia; Dal Monte, Pier Roberto; Ideo, Gaetano; Forti, Domenico; Mazziotti, Alighieri; Cavallari, Antonino; Bernardi, Mauro.

In: Journal of Hepatology, Vol. 29, No. 6, 12.1998, p. 985-989.

Research output: Contribution to journalArticle

Andreone, P, Caraceni, P, Grazi, GL, Belli, L, Milandri, GL, Ercolani, G, Jovine, E, D'Errico, A, Dal Monte, PR, Ideo, G, Forti, D, Mazziotti, A, Cavallari, A & Bernardi, M 1998, 'Lamivudine treatment for acute hepatitis B after liver transplantation', Journal of Hepatology, vol. 29, no. 6, pp. 985-989. https://doi.org/10.1016/S0168-8278(98)80127-X
Andreone, Pietro ; Caraceni, Paolo ; Grazi, Gian Luca ; Belli, Luca ; Milandri, Gian Luigi ; Ercolani, Giorgio ; Jovine, Elio ; D'Errico, Antonia ; Dal Monte, Pier Roberto ; Ideo, Gaetano ; Forti, Domenico ; Mazziotti, Alighieri ; Cavallari, Antonino ; Bernardi, Mauro. / Lamivudine treatment for acute hepatitis B after liver transplantation. In: Journal of Hepatology. 1998 ; Vol. 29, No. 6. pp. 985-989.
@article{d394b67e95864f608b01b3b70cd56f48,
title = "Lamivudine treatment for acute hepatitis B after liver transplantation",
abstract = "Background/Aims: Acute hepatitis caused by recurrent or de novo hepatitis B virus (HBV) infection after liver transplantation frequently induces aggressive disease leading to liver failure. The aim of this study was to determine the efficacy and safety of lamivudine treatment in post- transplant acute hepatitis B. Method: Twelve patients with acute hepatitis B were started on lamivudine 100 mg po daily within 8 weeks of the appearance of HBsAg. One patient was excluded after I month because of hepatocellular carcinoma recurrence. Patients were followed for an average of 68.6 weeks (range 32-108), and were clinically and biochemically evaluated on a monthly basis. They had a histological assessment at baseline, after at least 6 months, and whenever clinically indicated. Results: Basal HBV-DNA ranged between 13 and 1288 pg/ml and serum alanine aminotransferase between 97 and 1036 U/l. HBV-DNA became undetectable within 8 weeks and transaminases normalized within 24 weeks in all cases. At the last visit, eight patients (73{\%}) remained HBV-DNA negative by liquid hybridization and had normal or close to normal alanine aminotransferase. Five patients (45{\%}) were also HBsAg negative and HBV-DNA negative by polymerase chain reaction. HBV-DNA and transaminase breakthrough occurred in three patients (27{\%}). Histology after 6-9 months showed chronic hepatitis in seven patients. Lamivudine was well tolerated without serious adverse reactions. Conclusions: These results indicate that lamivudine treatment induces sustained inhibition of viral replication and normalization of transaminases in the majority of post- transplant patients with acute hepatitis B. HBsAg loss may be achieved in a considerable number of cases. Although viral resistance is relatively frequent, early initiation of lamivudine appears to be effective and safe.",
keywords = "Lamivudine, Liver transplantation, Recurrent or de novo acute hepatitis B",
author = "Pietro Andreone and Paolo Caraceni and Grazi, {Gian Luca} and Luca Belli and Milandri, {Gian Luigi} and Giorgio Ercolani and Elio Jovine and Antonia D'Errico and {Dal Monte}, {Pier Roberto} and Gaetano Ideo and Domenico Forti and Alighieri Mazziotti and Antonino Cavallari and Mauro Bernardi",
year = "1998",
month = "12",
doi = "10.1016/S0168-8278(98)80127-X",
language = "English",
volume = "29",
pages = "985--989",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Lamivudine treatment for acute hepatitis B after liver transplantation

AU - Andreone, Pietro

AU - Caraceni, Paolo

AU - Grazi, Gian Luca

AU - Belli, Luca

AU - Milandri, Gian Luigi

AU - Ercolani, Giorgio

AU - Jovine, Elio

AU - D'Errico, Antonia

AU - Dal Monte, Pier Roberto

AU - Ideo, Gaetano

AU - Forti, Domenico

AU - Mazziotti, Alighieri

AU - Cavallari, Antonino

AU - Bernardi, Mauro

PY - 1998/12

Y1 - 1998/12

N2 - Background/Aims: Acute hepatitis caused by recurrent or de novo hepatitis B virus (HBV) infection after liver transplantation frequently induces aggressive disease leading to liver failure. The aim of this study was to determine the efficacy and safety of lamivudine treatment in post- transplant acute hepatitis B. Method: Twelve patients with acute hepatitis B were started on lamivudine 100 mg po daily within 8 weeks of the appearance of HBsAg. One patient was excluded after I month because of hepatocellular carcinoma recurrence. Patients were followed for an average of 68.6 weeks (range 32-108), and were clinically and biochemically evaluated on a monthly basis. They had a histological assessment at baseline, after at least 6 months, and whenever clinically indicated. Results: Basal HBV-DNA ranged between 13 and 1288 pg/ml and serum alanine aminotransferase between 97 and 1036 U/l. HBV-DNA became undetectable within 8 weeks and transaminases normalized within 24 weeks in all cases. At the last visit, eight patients (73%) remained HBV-DNA negative by liquid hybridization and had normal or close to normal alanine aminotransferase. Five patients (45%) were also HBsAg negative and HBV-DNA negative by polymerase chain reaction. HBV-DNA and transaminase breakthrough occurred in three patients (27%). Histology after 6-9 months showed chronic hepatitis in seven patients. Lamivudine was well tolerated without serious adverse reactions. Conclusions: These results indicate that lamivudine treatment induces sustained inhibition of viral replication and normalization of transaminases in the majority of post- transplant patients with acute hepatitis B. HBsAg loss may be achieved in a considerable number of cases. Although viral resistance is relatively frequent, early initiation of lamivudine appears to be effective and safe.

AB - Background/Aims: Acute hepatitis caused by recurrent or de novo hepatitis B virus (HBV) infection after liver transplantation frequently induces aggressive disease leading to liver failure. The aim of this study was to determine the efficacy and safety of lamivudine treatment in post- transplant acute hepatitis B. Method: Twelve patients with acute hepatitis B were started on lamivudine 100 mg po daily within 8 weeks of the appearance of HBsAg. One patient was excluded after I month because of hepatocellular carcinoma recurrence. Patients were followed for an average of 68.6 weeks (range 32-108), and were clinically and biochemically evaluated on a monthly basis. They had a histological assessment at baseline, after at least 6 months, and whenever clinically indicated. Results: Basal HBV-DNA ranged between 13 and 1288 pg/ml and serum alanine aminotransferase between 97 and 1036 U/l. HBV-DNA became undetectable within 8 weeks and transaminases normalized within 24 weeks in all cases. At the last visit, eight patients (73%) remained HBV-DNA negative by liquid hybridization and had normal or close to normal alanine aminotransferase. Five patients (45%) were also HBsAg negative and HBV-DNA negative by polymerase chain reaction. HBV-DNA and transaminase breakthrough occurred in three patients (27%). Histology after 6-9 months showed chronic hepatitis in seven patients. Lamivudine was well tolerated without serious adverse reactions. Conclusions: These results indicate that lamivudine treatment induces sustained inhibition of viral replication and normalization of transaminases in the majority of post- transplant patients with acute hepatitis B. HBsAg loss may be achieved in a considerable number of cases. Although viral resistance is relatively frequent, early initiation of lamivudine appears to be effective and safe.

KW - Lamivudine

KW - Liver transplantation

KW - Recurrent or de novo acute hepatitis B

UR - http://www.scopus.com/inward/record.url?scp=0032404086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032404086&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(98)80127-X

DO - 10.1016/S0168-8278(98)80127-X

M3 - Article

VL - 29

SP - 985

EP - 989

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -